Lead Product(s) : Dersimelagon
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mitsubishi Initiates Phase 3 Clinical Trial for MT-7117
Details : The Phase-2 study was a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of MT-7117 in subjects with diffuse cutaneous systemic sclerosis.
Product Name : MT-7117
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2021
Lead Product(s) : Dersimelagon
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable